{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:02:11Z","timestamp":1779321731858,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008015","name":"Australian National Fabrication Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcyt.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T23:21:38Z","timestamp":1715296898000},"page":"1264-1274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enrichment of T-lymphocytes from leukemic blood using inertial microfluidics toward improved chimeric antigen receptor-T cell manufacturing"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-2910","authenticated-orcid":false,"given":"Mona T.","family":"Elsemary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle F.","family":"Maritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid Ebrahimi","family":"Warkiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-2842","authenticated-orcid":false,"given":"Benjamin","family":"Thierry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.05.005_bib0001","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0002","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0003","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s40883-019-00124-3","article-title":"The challenge of variability in chimeric antigen receptor t cell manufacturing","volume":"6","author":"Ad","year":"2020","journal-title":"Regen Eng Transl Med"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.imlet.2019.10.014","article-title":"CART manufacturing process and reasons for academy-pharma collaboration","volume":"217","author":"Egri","year":"2020","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800239","article-title":"Scaling up the manufacturing process of adoptive T cell immunotherapy","volume":"14","author":"Dai","year":"2019","journal-title":"Biotechnol J"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fmed.2018.00150","article-title":"Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges","volume":"5","author":"Iyer","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0008","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0009","unstructured":"Bryan WW. Tisagenlecleucel Novartis Pharmaceuticals Corporation 2017. Presented at the Oncologic Drugs Advisory Committee Meeting, U.S. FDA, 12 July 2017. Accessed on 27 May 2024. https:\/\/www.fda.gov\/media\/106489\/download."},{"key":"10.1016\/j.jcyt.2024.05.005_bib0010","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0011","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti-CD19-CAR engineered T cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"issue":"22","key":"10.1016\/j.jcyt.2024.05.005_bib0012","first-page":"00611","article-title":"Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications","volume":"S1465\u20133249","author":"Teoh","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.eng.2018.12.003","article-title":"Quality control and nonclinical research on CAR-T cell products: general principles and key issues","volume":"5","author":"Li","year":"2019","journal-title":"Engineering"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0014","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/trf.15287","article-title":"Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics","volume":"59","author":"Elavia","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2006-11-010389","article-title":"Suppression of T-cell functions by human granulocyte arginase","volume":"108","author":"Munder","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4049\/jimmunol.156.2.523","article-title":"Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion","volume":"156","author":"Munn","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0018","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1073\/pnas.1800695115","article-title":"Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers","volume":"115","author":"Feng","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0019","doi-asserted-by":"crossref","first-page":"13851","DOI":"10.1021\/jacs.2c05349","article-title":"Discovery of a transferrin receptor 1-binding aptamer and its application in cancer cell depletion for adoptive T-cell therapy manufacturing","volume":"144","author":"Cheng","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.omtm.2021.10.006","article-title":"Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL","volume":"23","author":"Deng","year":"2021","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0021","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0022","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/ijc.32201","article-title":"Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients","volume":"145","author":"Stock","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0023","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12967-017-1160-5","article-title":"Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells","volume":"15","author":"Stroncek","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0025","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther \u2013 Oncolytics"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0026","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0027","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0028","first-page":"3201","article-title":"Results of using automated Clinimacs prodigy for CD34 selection from mobilized peripheral blood stem cell products","volume":"130","author":"Bateman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0029","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1016\/S0006-3495(99)77483-7","article-title":"Dielectric properties of human leukocyte subpopulations determined by electrorotation as a cell separation criterion","volume":"76","author":"Yang","year":"1999","journal-title":"Biophys J"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0030","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1039\/C9LC00181F","article-title":"Label-free separation of leukocyte subpopulations using high throughput multiplex acoustophoresis","volume":"19","author":"Urbansky","year":"2019","journal-title":"Lab Chip"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/mi7060101","article-title":"Affinity-bead-mediated enrichment of CD8+ lymphocytes from peripheral blood progenitor cell products using acoustophoresis","volume":"7","author":"Urbansky","year":"2016","journal-title":"Micromachines (Basel)"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0032","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cyto.a.22507","article-title":"Efficient purification of CD4+ lymphocytes from peripheral blood progenitor cell products using affinity bead acoustophoresis","volume":"85","author":"Lenshof","year":"2014","journal-title":"Cytometry A"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0033","doi-asserted-by":"crossref","DOI":"10.1063\/1.4821628","article-title":"On-chip magnetophoretic isolation of CD4\u2009+\u2009T cells from blood","volume":"7","author":"Darabi","year":"2013","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0034","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1039\/D3LC00622K","article-title":"Expanding CAR-T cell immunotherapy horizons through microfluidics","volume":"24","author":"Kim","year":"2024","journal-title":"Lab Chip"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bios.2014.07.029","article-title":"Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices","volume":"63","author":"Halldorsson","year":"2015","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0036","doi-asserted-by":"crossref","first-page":"13798","DOI":"10.1038\/s41598-022-16748-5","article-title":"A high-throughput microfluidic device based on controlled incremental filtration to enable centrifugation-free, low extracorporeal volume leukapheresis","volume":"12","author":"Lezzar","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0037","unstructured":"Barker C. Modernizing cell therapy manufacturing to reduce vein-to-vein times. BioInsights. n.d.https:\/\/insights.bio\/cell-and-gene-therapy-insights\/journal\/article\/2907\/Modernizing-cell-therapy-manufacturing-to-reduce-vein-to-vein-times [accessed 05.09.23]."},{"key":"10.1016\/j.jcyt.2024.05.005_bib0038","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/2472630317751214","article-title":"Deterministic lateral displacement: the next-generation CAR T-cell processing?","volume":"23","author":"Campos-Gonz\u00e1lez","year":"2018","journal-title":"SLAS Technol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0039","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/cyto.a.23019","article-title":"Automated leukocyte processing by microfluidic deterministic lateral displacement","volume":"89","author":"Civin","year":"2016","journal-title":"Cytometry Part A"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0040","doi-asserted-by":"crossref","unstructured":"Philippidis A. Draper aims high as a kite against cancer. GEN \u2013 Genetic Engineering and Biotechnology News, https:\/\/www.genengnews.com\/gen-edge\/draper-aims-high-as-a-kite-against-cancer\/; 2020 [accessed 05.09.23].","DOI":"10.1089\/genedge.2.1.63"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1063\/5.0109017","article-title":"Rosette-induced separation of T cells by acoustophoresis","volume":"16","author":"Vijayakumar","year":"2022","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0042","unstructured":"McCall D, Singh A, Biotechnology S. Enabling GMP-ready cell sorting. n.d."},{"key":"10.1016\/j.jcyt.2024.05.005_bib0043","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jcyt.2023.05.003","article-title":"Feasibility of an acoustophoresis-based system for a high-throughput cell washing: application to bioproduction","volume":"25","author":"Sugier","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0044","unstructured":"Cellular Highways: advancing cell sorting technology. TTP. n.d.https:\/\/www.ttp.com\/case-studies\/cellular-highways-advancing-cell-sorting-technology\/[accessed 14.09.23]."},{"key":"10.1016\/j.jcyt.2024.05.005_bib0045","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1039\/C4AN00355A","article-title":"An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells","volume":"139","author":"Warkiani","year":"2014","journal-title":"Analyst"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0046","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1039\/C8LC00250A","article-title":"Continuous removal of small nonviable suspended mammalian cells and debris from bioreactors using inertial microfluidics","volume":"18","author":"Kwon","year":"2018","journal-title":"Lab Chip"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0047","doi-asserted-by":"crossref","DOI":"10.1063\/1.4819275","article-title":"Continuous separation of blood cells in spiral microfluidic devices","volume":"7","author":"Nivedita","year":"2013","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/admt.201800066","article-title":"Isolation of circulating fetal trophoblasts using inertial microfluidics for noninvasive prenatal testing","volume":"3","author":"Winter","year":"2018","journal-title":"Adv Mater Technol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0049","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1109\/TBCAS.2017.2735440","article-title":"High-throughput separation of white blood cells from whole blood using inertial microfluidics","volume":"11","author":"Zhang","year":"2017","journal-title":"IEEE Trans Biomed Circuits Syst"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0050","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.1038\/srep11018","article-title":"Membrane-less microfiltration using inertial microfluidics","volume":"5","author":"Warkiani","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0051","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1039\/b807107a","article-title":"Continuous particle separation in spiral microchannels using dean flows and differential migration","volume":"8","author":"Bhagat","year":"2008","journal-title":"Lab Chip"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0052","doi-asserted-by":"crossref","first-page":"18892","DOI":"10.1073\/pnas.0704958104","article-title":"Continuous inertial focusing, ordering, and separation of particles in microchannels","volume":"104","author":"Di Carlo","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0053","doi-asserted-by":"crossref","first-page":"54101","DOI":"10.1063\/1.4819275","article-title":"Continuous separation of blood cells in spiral microfluidic devices","volume":"7","author":"Nivedita","year":"2013","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0054","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0055","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/ijms21051825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0056","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12865-019-0286-z","article-title":"Phenotypic and functional stability of leukocytes from human peripheral blood samples: considerations for the design of immunological studies","volume":"20","author":"Navas","year":"2019","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0058","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0059","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.beha.2010.02.001","article-title":"Chronic lymphocytic leukemia: a disease of activated monoclonal B cells","volume":"23","author":"Damle","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0060","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0061","series-title":"Leukaemia diagnosis","first-page":"249","article-title":"Acute lymphoblastic leukaemia and acute leukaemia of ambiguous lineage","author":"Bain","year":"2017"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0062","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2228-7477.150428","article-title":"Recognition of acute lymphoblastic leukemia cells in microscopic images using k-means clustering and support vector machine classifier","volume":"5","author":"Amin","year":"2015","journal-title":"J Med Signals Sens"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0063","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.leu.2400847","article-title":"Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia","volume":"11","author":"Lacombe","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0064","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12288-017-0896-7","article-title":"B-acute lymphoblastic leukemia with bright CD45 and moderate side scatter simulating monocytoid population: an unusual phenotype","volume":"34","author":"Gupta","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0065","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/386165","article-title":"Bone marrow cells in acute lymphoblastic leukemia create a proinflammatory microenvironment influencing normal hematopoietic differentiation fates","volume":"2015","author":"Vilchis-Ordo\u00f1ez","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0067","first-page":"20","article-title":"BAFF levels are elevated in paediatric patients with acute lymphoblastic leukaemia compared to other B-lineage neoplasms","volume":"1","author":"Bienertova-Vasku","year":"2012","journal-title":"J Hematol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0068","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood.V120.21.1466.1466","article-title":"Precursor B cell acute lymphoblastic leukemia induces pro-leukemic changes in the bone marrow microenvironment that contribute to therapeutic resistance","volume":"120","author":"Chien","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0069","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/sj.leu.2403876","article-title":"Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias","volume":"19","author":"Amin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.24252","article-title":"Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"91","author":"DiNardo","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0071","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14569","article-title":"Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma","volume":"58","author":"Ceppi","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0072","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jcyt.2017.02.190","article-title":"Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL)","volume":"19","author":"Davis","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0073","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11899-017-0395-9","article-title":"Considerations in T cell therapy product development for B cell leukemia and lymphoma immunotherapy","volume":"12","author":"Fesnak","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0074","unstructured":"Figueiredo M. CAR T-cell therapy Tecartus for mantle cell lymphoma gets FDA Nod 2020. https:\/\/immuno-oncologynews.com\/2020\/07\/28\/car-t-cell-therapy-tecartus-granted-fda-approval-for-mantle-cell-lymphoma\/[accessed 14.09.20]."},{"key":"10.1016\/j.jcyt.2024.05.005_bib0075","article-title":"Kite flies high with second CAR-T approval \u2013 bioprocess insider","author":"Stanton","year":"2020","journal-title":"Bioprocess Int"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0076","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0077","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0078","article-title":"Electroporation characteristics of human primary T cells","author":"Aksoy","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0079","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1179\/1607845415Y.0000000025","article-title":"Increased regulatory T cells in acute lymphoblastic leukemia patients","volume":"20","author":"Idris","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.886637","article-title":"Influence of culture conditions on ex vivo expansion of T lymphocytes and their function for therapy: current insights and open questions","volume":"10","author":"Sudarsanam","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0081","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antib10020017","article-title":"Tinkering under the Hood: metabolic optimisation of CAR-T cell therapy","volume":"10","author":"Jenkins","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0082","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2816498","article-title":"CD4+CD25highCD127low\/-FoxP3+ regulatory T-cell population in acute leukemias: a review of the literature","volume":"2019","author":"Nied\u017awiecki","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0083","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","article-title":"T regulatory cells and priming the suppressive tumor microenvironment","volume":"10","author":"Paluskievicz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0084","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157822","article-title":"Depletion of regulatory T cells induces high numbers of dendritic cells and unmasks a subset of anti-tumour CD8+CD11c+ PD-1lo effector t cells","volume":"11","author":"Goudin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0086","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines","volume":"112","author":"Morse","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0087","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.cji.0000187959.45803.0c","article-title":"Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2","volume":"29","author":"Attia","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0088","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1189\/jlb.0603272","article-title":"The main function of IL-2 is to promote the development of T regulatory cells","volume":"74","author":"Malek","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0089","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/2472630317749944","article-title":"Purification of lymphocytes by acoustic separation in plastic microchannels","volume":"23","author":"Lissandrello","year":"2018","journal-title":"SLAS Technol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0090","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.073","article-title":"Diagnosis and subclassification of acute lymphoblastic leukemia","volume":"6","author":"Chiaretti","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0091","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5858\/arpa.2019-0182-RA","article-title":"A practical approach to diagnosis of B-cell lymphomas with diffuse large cell morphology","volume":"144","author":"King","year":"2020","journal-title":"Arch Path Lab"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202101018","article-title":"Inertial microfluidic purification of CAR-T-cell products","volume":"6","author":"Elsemary","year":"2022","journal-title":"Adv Biol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0093","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/mi14040877","article-title":"Microfluidic chips: emerging technologies for adoptive cell immunotherapy","volume":"14","author":"Tian","year":"2023","journal-title":"Micromachines"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0094","article-title":"Producing CAR T cell therapy at a lower cost","year":"2020","journal-title":"News-Medical"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0095","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0096","unstructured":"Decentralized CAR-T Manufacturing Reduces Costs & Complexity, Expands Access. n.d. https:\/\/www.cellandgene.com\/doc\/decentralized-car-t-manufacturing-reduces-costs-complexity-expands-access-0001 [accessed 21.04.24]."},{"key":"10.1016\/j.jcyt.2024.05.005_bib0097","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/diagnostics13081394","article-title":"Fabrication of a low-cost microfluidic device for high-throughput drug testing on static and dynamic cancer spheroid culture models","volume":"13","author":"Do","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1176557","article-title":"Breaking the clean room barrier: exploring low-cost alternatives for microfluidic devices","volume":"11","author":"Rodr\u00edguez","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0099","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/trf.14094","article-title":"Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with high-risk leukemia","volume":"57","author":"Even-Or","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.05.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1063\/1.5096190","article-title":"Scalable high-throughput acoustophoresis in arrayed plastic microchannels","volume":"13","author":"Dubay","year":"2019","journal-title":"Biomicrofluidics"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492400714X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492400714X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:46Z","timestamp":1762546186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492400714X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S146532492400714X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enrichment of T-lymphocytes from leukemic blood using inertial microfluidics toward improved chimeric antigen receptor-T cell manufacturing","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}